Skip to main content
ChemPartner PharmaTech Co., Ltd. logo

ChemPartner PharmaTech Co., Ltd. — Investor Relations & Filings

Ticker · 300149 ISIN · CNE100000Y27 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,256 across all filing types
Latest filing 2017-06-12 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300149

About ChemPartner PharmaTech Co., Ltd.

https://www.chempartner.com

ChemPartner PharmaTech Co., Ltd. is a global research and development organization providing comprehensive drug discovery and development services. Operating as a Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), the company supports pharmaceutical and biotechnology clients through an integrated service platform. Core capabilities include medicinal chemistry, biology, pharmacology, drug metabolism and pharmacokinetics (DMPK), and toxicology. The organization also offers specialized expertise in biologics discovery, protein engineering, and antibody development. ChemPartner facilitates the transition from early-stage research to clinical development through its pharmaceutical development and manufacturing capabilities, utilizing advanced technology to accelerate the discovery and production of novel therapeutic agents.

Recent filings

Filing Released Lang Actions
广发证券股份有限公司关于公司发行股份及支付现金购买资产并募集配套资金暨关联交易预案之独立财务顾问核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed independent financial advisor's verification opinion related to a major asset restructuring transaction involving issuance of shares and cash payment to purchase assets, along with a fundraising plan. It references specific regulatory frameworks such as the "Company Law", "Securities Law", "Restructuring Management Measures", and various Chinese securities regulations. The document includes detailed transaction terms, legal and regulatory compliance checks, and financial valuations. It is not a simple announcement but a comprehensive advisory report on a major asset restructuring transaction. This fits the category of a Capital/Financing Update (CAP) because it involves issuance of shares, cash payment for asset acquisition, and fundraising activities. It is not an Annual Report, Audit Report, or Merger & Acquisition filing per se, but a detailed independent financial advisor opinion on a financing and asset purchase transaction. The document length (15,000 characters) and content confirm it is a full report, not just an announcement. Therefore, the best classification is CAP with high confidence.
2017-06-12 Chinese
第三届监事会第十七次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of resolutions passed at the 17th meeting of the third Supervisory Board of Quantum Hi-Tech (China) Biological Co., Ltd. It details approvals related to the use of surplus raised funds for a major asset restructuring cash consideration, a 2017 stock option incentive plan and its implementation rules, and verification of the incentive recipients. The document includes voting results and states that these matters will be submitted to the shareholders' meeting for approval. The content is procedural and governance-related, focusing on supervisory board decisions and compliance with relevant laws and regulations. It does not contain financial statements, earnings data, or detailed financial analysis. It is not a full annual or interim report, nor an earnings release or audit report. It is not a proxy solicitation or voting results announcement. The document is best classified as a Regulatory Filing (RNS) because it is a formal regulatory announcement of supervisory board resolutions and related governance matters that do not fit other specific categories.
2017-06-12 Chinese
关于重大资产重组的一般风险提示公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Quantum Hi-Tech (China) Biological Co., Ltd. regarding risks related to a major asset restructuring. It references prior announcements about stock suspension due to planning a major asset purchase and mentions regulatory compliance and risk warnings to investors. The content focuses on risk disclosure and regulatory compliance related to a significant asset reorganization, not the actual transaction details or financial statements. The document length is short (731 characters), and it serves as a risk warning announcement rather than a full report or detailed financial disclosure. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to updates on major asset restructuring and associated risks, which are financing-related activities.
2017-06-12 Chinese
北京国枫律师事务所关于公司2017年股票期权激励计划的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the legality and compliance of a 2017 stock option incentive plan for a listed company, Quantum Hi-Tech (China) Biological Co., Ltd. It extensively discusses the stock option plan's compliance with relevant laws, regulations, and company procedures. The document is not a financial report, earnings release, or management discussion but a legal opinion on a specific corporate action related to stock options. This type of document fits best under the category of Regulatory Filings (RNS), as it is a compliance/legal opinion rather than a financial report or announcement of voting results or management changes. The document length (8439 characters) and content confirm it is not a brief announcement but a detailed legal opinion letter, which is typical for RNS filings.
2017-06-12 Chinese
2017年股票期权激励计划（草案）
Governance Information Classification · 95% confidence The document is a detailed draft of a 2017 stock option incentive plan for a company named 量子高科 (Quantum High-Tech). It includes comprehensive information about the plan's purpose, legal basis, management, scope, stock option quantities, pricing, conditions for granting and exercising options, accounting treatment, and implementation procedures. The document references relevant laws and regulations, such as the Company Law, Securities Law, and stock incentive management measures, and includes detailed financial and procedural data. It is not a report of financial results, audit, or earnings, nor is it a brief announcement or a transcript. It is a formal plan document related to stock-based compensation and incentive arrangements for management and key personnel. This type of document fits best under the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices, including stock option plans and incentive schemes.
2017-06-12 Chinese
独立董事关于第三届董事会第二十八次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from independent directors regarding a major asset restructuring involving issuance of shares and cash payment, as well as a stock option incentive plan. It discusses legal compliance, transaction details, pricing, and approvals needed. The content focuses on governance and management opinions related to board meeting agenda items, rather than presenting financial statements or earnings data. It is not a full annual or interim report, nor an earnings release or audit report. It is also not a simple announcement or certification. The document is a detailed board/management related opinion on corporate actions and governance matters, fitting the Board/Management Information (MANG) category.
2017-06-12 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.